🚀 VC round data is live in beta, check it out!
Quince Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Quince Therapeutics and similar public comparables like Nanogroup, Gensight Biologics, Advicenne, Poltreg and more.
Quince Therapeutics Overview
About Quince Therapeutics
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Founded
2012
HQ
Employees
36
Website
Sectors
Financials (LTM)
EV
$23M
Quince Therapeutics Financials
Quince Therapeutics reported last 12-month revenue of —.
In the same LTM period, Quince Therapeutics generated had net loss of ($44M).
Revenue (LTM)
Quince Therapeutics P&L
In the most recent fiscal year, Quince Therapeutics reported revenue of — and EBITDA of ($50M).
Quince Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($50M) | XXX | XXX | XXX |
| Net Profit | ($44M) | XXX | ($52M) | XXX | XXX | XXX |
| Net Debt | — | — | $12M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Quince Therapeutics Stock Performance
Quince Therapeutics has current market cap of $23M, and enterprise value of $23M.
Market Cap Evolution
Quince Therapeutics' stock price is $1.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23M | $23M | 0.0% | XXX | XXX | XXX | $-3.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialQuince Therapeutics Valuation Multiples
Quince Therapeutics trades at (0.5x) EV/EBITDA.
Quince Therapeutics Financial Valuation Multiples
As of April 20, 2026, Quince Therapeutics has market cap of $23M and EV of $23M.
Equity research analysts estimate Quince Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Quince Therapeutics has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $23M | XXX | $23M | XXX | XXX | XXX |
| EV (current) | $23M | XXX | $23M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | (0.6x) | XXX | (0.5x) | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Quince Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Quince Therapeutics Margins & Growth Rates
Quince Therapeutics' revenue in the last fiscal year grew by —.
Quince Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.4M for the same period.
Quince Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Quince Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Quince Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanogroup | XXX | XXX | XXX | XXX | XXX | XXX |
| Gensight Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Advicenne | XXX | XXX | XXX | XXX | XXX | XXX |
| Poltreg | XXX | XXX | XXX | XXX | XXX | XXX |
| Arterra Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Quince Therapeutics M&A Activity
Quince Therapeutics acquired XXX companies to date.
Last acquisition by Quince Therapeutics was on XXXXXXXX, XXXXX. Quince Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Quince Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialQuince Therapeutics Investment Activity
Quince Therapeutics invested in XXX companies to date.
Quince Therapeutics made its latest investment on XXXXXXXX, XXXXX. Quince Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Quince Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Quince Therapeutics
| When was Quince Therapeutics founded? | Quince Therapeutics was founded in 2012. |
| Where is Quince Therapeutics headquartered? | Quince Therapeutics is headquartered in United States. |
| How many employees does Quince Therapeutics have? | As of today, Quince Therapeutics has over 36 employees. |
| Who is the CEO of Quince Therapeutics? | Quince Therapeutics' CEO is Dirk Thye. |
| Is Quince Therapeutics publicly listed? | Yes, Quince Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Quince Therapeutics? | Quince Therapeutics trades under QNCX ticker. |
| When did Quince Therapeutics go public? | Quince Therapeutics went public in 2019. |
| Who are competitors of Quince Therapeutics? | Quince Therapeutics main competitors are Nanogroup, Gensight Biologics, Advicenne, Poltreg. |
| What is the current market cap of Quince Therapeutics? | Quince Therapeutics' current market cap is $23M. |
| Is Quince Therapeutics profitable? | No, Quince Therapeutics is not profitable. |
| What is the current net income of Quince Therapeutics? | Quince Therapeutics' last 12 months net income is ($44M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.